Xeloda in Combination with Avastin as first-LIne treatment for HER2-negative metastatic Breast cancer

Trial Profile

Xeloda in Combination with Avastin as first-LIne treatment for HER2-negative metastatic Breast cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2007

At a glance

  • Drugs Bevacizumab; Capecitabine
  • Indications Advanced breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms XCALIBr
  • Sponsors Roche
  • Most Recent Events

    • 22 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top